SCHEMBL22403785

SCHEMBL22403785

CC(C)(C)Cc1cncc(CC(C)(C)Cc2ccccc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.42
TAAR1 Q96RJ0 1/20 0.42
CYP2D6 P10635 2/20 0.40
LMNA P02545 1/20 0.40
ESR1 P03372 1/20 0.38
FDPS P14324 1/20 0.37
GRN P28799 1/20 0.37
SORT1 Q99523 1/20 0.37
CYP3A4 P08684 3/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HIF1A Q16665 1/20 0.37
KCNA5 P22460 1/20 0.37
TRPA1 O75762 1/20 0.36
TBXAS1 P24557 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24630680 0.86 ESR1 (0.38) CYP2D6ESR1FDPSCYP3A4CYP1A2
SCHEMBL10223951 0.82 ESR1 (0.41) ESR1FDPSTBXAS1
SCHEMBL16133339 0.79 FDPS (0.57) FDPSCYP3A4CYP11B1CYP11B2
SCHEMBL347187 0.78 SLC6A2 (0.64) SLC6A2TAAR1CYP2D6LMNAESR1
SCHEMBL1572105 0.78 SLC6A2 (0.64) SLC6A2TAAR1CYP2D6LMNAFDPS
Ammonia Solution, Strong SCHEMBL10608295 0.76 SLC6A2 (0.61) SLC6A2TAAR1CYP2D6LMNAESR1
SCHEMBL21316558 0.75 ESR1 (0.35) ESR1
SCHEMBL26433336 0.72 GRN (0.41) SLC6A2TAAR1CYP2D6LMNAGRN
SCHEMBL18372375 0.72 KIF11 (0.38) CYP2D6LMNACYP3A4TBXAS1CYP11B1
SCHEMBL18924302 0.72 CHRNB2 (0.35) ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 SLC6A2 2539/4885TAAR1 4258/4885CYP2D6 3804/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SLC6A2 2539/4885TAAR1 4258/4885CYP2D6 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.